Showing 7261-7270 of 7664 results for "".
- Positive Findings Published for Provectus Pharmaceuticals' PV-10https://practicaldermatology.com/news/20130726-positive_findings_published_for_provectus_pharmaceuticals_pv-10/2459491/Positive research conducted at the Moffitt Cancer Center with intralesional PV-10 has been published in PLOS ONE, an international, peer-reviewed, open-access, online publication,
- Mentor, Medicis Unveiling Joint New Physician Loyalty Programhttps://practicaldermatology.com/news/20130717-mentor_medicis_unveiling_joint_new_physician_loyalty_program/2459494/Mentor Worldwide, LLC and Valeant's Medicis division have entered into a Collaboration Agreement to form a joint physician loyalty program called the M2VP P
- Galen Acquires Local Dermal Analgesia Drug Synerahttps://practicaldermatology.com/news/20130716-galen_acquires_local_dermal_analgesia_drug_synera/2459495/Galen, a Northern Ireland based pharmaceutical company, has acquired Synera® (lidocaine 70mg/tetracaine 70mg) topical patch from ZARS Pharma, Inc., a wholly owned subsidiary of Nuvo Research Inc. Synera® is indicated for use on intact skin t
- ASDS Database Helps Residents Find Fellowships and Opportunitieshttps://practicaldermatology.com/news/20130716-asds_database_helps_residents_find_fellowships_and_opportunities/2459499/To help residents with the challenge of identifying suitable fellowship programs, the American Society for Dermatologic Surgery's (ASDS) new database, called the DermSurg Fellowship Finder, is a comprehensive source for all Mohs, procedural, cosmetic, and laser surgical fellowships in the US. The go
- Leading Scientist Behind SkinCeuticals Dies At 76https://practicaldermatology.com/news/20130712-dr_sheldon_pinnell_the_founding_father_of_topical_antioxidants_leading_scientist_behind_skinceuticals_and_chief_emeritus_of_the_division_of_dermatolog/2459500/Dr. Sheldon Pinnell, an internationally eminent scientist, dermatologist, leading scientist behind L'Oreal-owned SkinCeuticals, and J. Lamar Callaway Professor Emeritus of Dermatology and Chief Emeritus of the Division of Dermatology at Duke University, passed away peacefully in Durham, North Caroli
- Investigational Psoriasis Agent On Track for Regulatory Submission This Yearhttps://practicaldermatology.com/news/20130708-investigational_psoriasis_agent_on_track_for_regulatory_submission_this_year/2459501/Results from a Phase III trial showed that the experimental drug secukinumab (Novartis) showed superiority to etanercept (Enbrel, Amgen) at clearing skin in patients with moderate-to-severe plaque psoriasis. The FIXTURE trial, which randomized 1,307 patients with moderate-to-severe plaque psoriasis,
- Allergan Appoints Douglas S. Ingram as Presidenthttps://practicaldermatology.com/news/20130702-allergan_appoints_douglas_s_ingram_as_president/2459504/Douglas S. Ingram was appointed as President of Allergan. In this role, Mr. Ingram will lead the company's global commercial operations, with responsibility for the company's broad portfolio of pharmaceutical, consumer, and medical device product
- Naftin Gel 2% Approved for Interdigital-Type Tinea Pedishttps://practicaldermatology.com/news/20130702-naftin_gel_2_approved_for_interdigital-type_tinea_pedis/2459507/The FDA approved Naftin (naftifine HCl) Gel 2% for the treatment of interdigital-type tinea pedis from Merz North America. Naftin Gel 2% improves on the current formulation of Naftin Gel 1% by delivering the efficacy of naftifine hydochloride with
- Promising Data Presented for Viviscal Oral Supplement to Promote Hair Growthhttps://practicaldermatology.com/news/20130625-promising_data_presented_for_viviscal_oral_supplement_to_promote_hair_growth/2459510/An office-dispensed oral food supplement appears to promote existing hair growth for women suffering from temporary thinning hair, according to data presented at the World Hair Congress in Edinburgh, Scotland this spring. Subjects treated with Viviscal Hair Nourishment System
- Phase III Data Show Galderma's Topical Redness Reducer is Effective, Safehttps://practicaldermatology.com/news/20130625-phase_iii_data_show_galdermas_topical_redness_reducer_is_effective_safe/2459511/Topical brimonidine tartrate gel 0.5% is safe and effective for the management of erythema of rosacea, with benefit evidence as early as 30 minutes after application, new data show. (JDD, 12(6):650-656) Data from two identically designed randomized, double-blind, vehicle controlled phase III trials